Marc Scherlinger

Innovative therapies in rheumatoid arthritis: CAR T cells and bispecific antibodies.

Rheumatoid arthritis is a chronic immune-mediated inflammatory disease, and therapeutic strategies predominantly rely on continuous immunomodulation. Despite major advances with biological and targeted synthetic disease-modifying antirheumatic drugs, some patients develop persistent, objectively active inflammatory dis...

Next-generation immune cell engagers for B cell depletion in autoimmune diseases.

Immune reset after deep B-lineage depletion: remission is not reprogramming.

Full 'immune reset' should be defined operationally as durable restoration of self-tolerance despite persistent genetic susceptibility and other contributing pathogenic factors, supported by concordant evidence across disease-relevant tissues, B- and T-cell memory, functional antigen specificity and immune reconstituti...